Kennon Heard
Concepts (635)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acetaminophen | 39 | 2023 | 237 | 8.900 |
Why?
| Chemical and Drug Induced Liver Injury | 15 | 2023 | 125 | 5.030 |
Why?
| Analgesics, Non-Narcotic | 20 | 2022 | 117 | 4.610 |
Why?
| Drug Overdose | 30 | 2022 | 293 | 4.330 |
Why?
| Emergency Service, Hospital | 40 | 2023 | 1812 | 3.780 |
Why?
| Poisoning | 17 | 2017 | 110 | 3.200 |
Why?
| Poison Control Centers | 11 | 2023 | 84 | 2.800 |
Why?
| Alanine Transaminase | 14 | 2023 | 140 | 2.750 |
Why?
| Acetylcysteine | 11 | 2023 | 142 | 2.720 |
Why?
| Cannabis | 9 | 2020 | 384 | 2.600 |
Why?
| Cocaine | 10 | 2011 | 153 | 2.570 |
Why?
| Prescription Drugs | 9 | 2018 | 116 | 2.330 |
Why?
| Analgesics, Opioid | 8 | 2023 | 774 | 1.740 |
Why?
| Antidotes | 9 | 2020 | 135 | 1.610 |
Why?
| Legislation, Drug | 5 | 2017 | 78 | 1.560 |
Why?
| Cysteine | 4 | 2017 | 171 | 1.470 |
Why?
| Antipsychotic Agents | 7 | 2019 | 184 | 1.410 |
Why?
| Marijuana Use | 4 | 2021 | 167 | 1.340 |
Why?
| Male | 101 | 2022 | 55735 | 1.310 |
Why?
| Medication Errors | 5 | 2015 | 89 | 1.230 |
Why?
| Humans | 152 | 2023 | 115049 | 1.220 |
Why?
| Cocaine-Related Disorders | 5 | 2011 | 107 | 1.160 |
Why?
| Pain | 9 | 2020 | 709 | 1.150 |
Why?
| Female | 95 | 2022 | 59617 | 1.150 |
Why?
| Emergency Medicine | 6 | 2019 | 220 | 1.140 |
Why?
| Adult | 73 | 2022 | 30658 | 1.140 |
Why?
| Toxicology | 4 | 2021 | 36 | 1.130 |
Why?
| Drug Packaging | 2 | 2017 | 43 | 1.120 |
Why?
| Medication Reconciliation | 2 | 2016 | 25 | 1.020 |
Why?
| Dose-Response Relationship, Drug | 16 | 2017 | 1857 | 1.010 |
Why?
| Antidepressive Agents, Tricyclic | 5 | 2014 | 29 | 0.940 |
Why?
| Spider Bites | 5 | 2019 | 10 | 0.940 |
Why?
| Diphenhydramine | 4 | 2023 | 30 | 0.930 |
Why?
| Middle Aged | 54 | 2022 | 26830 | 0.920 |
Why?
| Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.910 |
Why?
| Young Adult | 30 | 2020 | 10498 | 0.910 |
Why?
| Antivenins | 5 | 2019 | 56 | 0.900 |
Why?
| Thiazoles | 4 | 2009 | 110 | 0.900 |
Why?
| Prescription Drug Monitoring Programs | 1 | 2023 | 13 | 0.880 |
Why?
| Spider Venoms | 4 | 2019 | 12 | 0.870 |
Why?
| Heart Arrest | 8 | 2018 | 289 | 0.860 |
Why?
| Referral and Consultation | 2 | 2020 | 633 | 0.850 |
Why?
| Benzodiazepines | 5 | 2011 | 116 | 0.840 |
Why?
| Muscarinic Antagonists | 3 | 2023 | 26 | 0.840 |
Why?
| Decision Support Systems, Clinical | 2 | 2023 | 177 | 0.840 |
Why?
| Seizures | 6 | 2011 | 341 | 0.830 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 299 | 0.790 |
Why?
| Piperazines | 4 | 2009 | 313 | 0.780 |
Why?
| Physostigmine | 2 | 2020 | 10 | 0.780 |
Why?
| Lorazepam | 2 | 2020 | 23 | 0.780 |
Why?
| Emergency Treatment | 4 | 2015 | 113 | 0.770 |
Why?
| Delirium | 2 | 2020 | 66 | 0.770 |
Why?
| Black Widow Spider | 4 | 2019 | 9 | 0.770 |
Why?
| Medical History Taking | 3 | 2018 | 115 | 0.760 |
Why?
| Dopamine Uptake Inhibitors | 3 | 2011 | 54 | 0.760 |
Why?
| Suicide, Attempted | 5 | 2012 | 314 | 0.740 |
Why?
| Abdominal Pain | 2 | 2019 | 135 | 0.720 |
Why?
| Retrospective Studies | 30 | 2022 | 12548 | 0.720 |
Why?
| Anti-Arrhythmia Agents | 4 | 2014 | 106 | 0.720 |
Why?
| Hospitals, Pediatric | 4 | 2018 | 477 | 0.700 |
Why?
| Back Pain | 1 | 2020 | 44 | 0.700 |
Why?
| Vasoconstrictor Agents | 4 | 2009 | 112 | 0.700 |
Why?
| Buprenorphine | 2 | 2020 | 134 | 0.690 |
Why?
| Patient Handoff | 1 | 2020 | 26 | 0.680 |
Why?
| Free Radical Scavengers | 2 | 2011 | 78 | 0.680 |
Why?
| Ketorolac | 1 | 2019 | 16 | 0.660 |
Why?
| Haloperidol | 1 | 2019 | 35 | 0.650 |
Why?
| Social Work | 1 | 2020 | 74 | 0.650 |
Why?
| Prospective Studies | 18 | 2023 | 6232 | 0.650 |
Why?
| Colorado | 15 | 2021 | 4089 | 0.640 |
Why?
| Pharmacoepidemiology | 1 | 2018 | 20 | 0.630 |
Why?
| Substance-Related Disorders | 5 | 2012 | 946 | 0.630 |
Why?
| Tertiary Care Centers | 3 | 2017 | 126 | 0.620 |
Why?
| Child | 28 | 2023 | 18407 | 0.620 |
Why?
| Gastric Lavage | 3 | 2009 | 9 | 0.620 |
Why?
| Vomiting | 6 | 2019 | 124 | 0.610 |
Why?
| Immunoglobulin Fab Fragments | 4 | 2019 | 69 | 0.600 |
Why?
| Cannabinoids | 3 | 2017 | 115 | 0.590 |
Why?
| Hypotension | 2 | 2022 | 114 | 0.590 |
Why?
| Drug Storage | 2 | 2017 | 59 | 0.590 |
Why?
| Accidents, Home | 1 | 2017 | 27 | 0.570 |
Why?
| Medical Marijuana | 2 | 2019 | 97 | 0.570 |
Why?
| Pulmonary Embolism | 3 | 2021 | 184 | 0.570 |
Why?
| Plant Preparations | 2 | 2015 | 23 | 0.560 |
Why?
| Fibrin Fibrinogen Degradation Products | 2 | 2007 | 81 | 0.560 |
Why?
| Calcium Gluconate | 1 | 2016 | 4 | 0.550 |
Why?
| Quaternary Ammonium Compounds | 1 | 2016 | 44 | 0.540 |
Why?
| Mobile Applications | 1 | 2018 | 140 | 0.540 |
Why?
| Hypocalcemia | 1 | 2016 | 31 | 0.540 |
Why?
| Health Records, Personal | 1 | 2016 | 24 | 0.530 |
Why?
| Practice Patterns, Physicians' | 3 | 2023 | 1178 | 0.530 |
Why?
| Treatment Outcome | 18 | 2020 | 9123 | 0.520 |
Why?
| Liver | 6 | 2022 | 1681 | 0.520 |
Why?
| Nonprescription Drugs | 4 | 2016 | 68 | 0.520 |
Why?
| Antidepressive Agents | 2 | 2012 | 195 | 0.520 |
Why?
| Child, Preschool | 13 | 2018 | 9093 | 0.510 |
Why?
| Blood Proteins | 1 | 2017 | 233 | 0.510 |
Why?
| Fat Emulsions, Intravenous | 2 | 2014 | 30 | 0.510 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 242 | 0.500 |
Why?
| Infant | 12 | 2018 | 7946 | 0.500 |
Why?
| Prescription Drug Misuse | 1 | 2015 | 38 | 0.500 |
Why?
| Emergency Medical Services | 4 | 2016 | 587 | 0.500 |
Why?
| Electrocardiography | 5 | 2013 | 562 | 0.490 |
Why?
| Adolescent | 27 | 2020 | 17864 | 0.470 |
Why?
| Electronic Health Records | 3 | 2023 | 799 | 0.460 |
Why?
| Asymptomatic Diseases | 2 | 2013 | 75 | 0.460 |
Why?
| Crime | 2 | 2011 | 59 | 0.450 |
Why?
| Observer Variation | 3 | 2010 | 298 | 0.450 |
Why?
| Arrhythmias, Cardiac | 3 | 2022 | 278 | 0.450 |
Why?
| Double-Blind Method | 7 | 2020 | 1665 | 0.450 |
Why?
| Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.440 |
Why?
| Aged | 27 | 2019 | 19122 | 0.440 |
Why?
| Energy Drinks | 1 | 2013 | 4 | 0.440 |
Why?
| Performance-Enhancing Substances | 1 | 2013 | 7 | 0.440 |
Why?
| Accidents | 1 | 2013 | 38 | 0.430 |
Why?
| Bradycardia | 1 | 2013 | 48 | 0.430 |
Why?
| Dronabinol | 4 | 2021 | 118 | 0.430 |
Why?
| Diet Surveys | 1 | 2013 | 78 | 0.430 |
Why?
| Poisons | 2 | 2023 | 21 | 0.430 |
Why?
| Plasmapheresis | 1 | 2013 | 22 | 0.430 |
Why?
| Amphotericin B | 1 | 2013 | 30 | 0.430 |
Why?
| Hematemesis | 1 | 2012 | 3 | 0.430 |
Why?
| Phytotherapy | 1 | 2013 | 66 | 0.420 |
Why?
| beta-Alanine | 1 | 2012 | 17 | 0.420 |
Why?
| Stomach Diseases | 1 | 2012 | 19 | 0.420 |
Why?
| Foreign Bodies | 2 | 2011 | 99 | 0.420 |
Why?
| Aspartate Aminotransferases | 3 | 2010 | 86 | 0.420 |
Why?
| Ethers | 1 | 2012 | 16 | 0.420 |
Why?
| Disease Models, Animal | 9 | 2011 | 3545 | 0.420 |
Why?
| Sulfonylurea Compounds | 2 | 2010 | 44 | 0.420 |
Why?
| Alcohol Drinking | 4 | 2012 | 655 | 0.410 |
Why?
| Antithrombins | 1 | 2012 | 49 | 0.410 |
Why?
| Citalopram | 1 | 2012 | 27 | 0.410 |
Why?
| Opioid-Related Disorders | 2 | 2020 | 414 | 0.410 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 2108 | 0.400 |
Why?
| Liver Function Tests | 7 | 2020 | 106 | 0.400 |
Why?
| Drug Administration Schedule | 5 | 2014 | 719 | 0.400 |
Why?
| Antifungal Agents | 1 | 2013 | 129 | 0.400 |
Why?
| C-Peptide | 2 | 2010 | 138 | 0.400 |
Why?
| Propafenone | 1 | 2011 | 2 | 0.400 |
Why?
| Thiophenes | 1 | 2012 | 108 | 0.400 |
Why?
| Aged, 80 and over | 15 | 2018 | 6357 | 0.390 |
Why?
| Burns | 2 | 2015 | 238 | 0.390 |
Why?
| Benzimidazoles | 1 | 2012 | 137 | 0.390 |
Why?
| Firesetting Behavior | 1 | 2011 | 1 | 0.390 |
Why?
| Infusions, Intravenous | 6 | 2013 | 372 | 0.390 |
Why?
| Charcoal | 4 | 2006 | 22 | 0.390 |
Why?
| Clinical Enzyme Tests | 2 | 2013 | 11 | 0.380 |
Why?
| Temperance | 2 | 2010 | 13 | 0.380 |
Why?
| Administration, Intravenous | 4 | 2016 | 125 | 0.380 |
Why?
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 9 | 0.370 |
Why?
| Brain Edema | 1 | 2011 | 60 | 0.370 |
Why?
| Evidence-Based Medicine | 4 | 2023 | 676 | 0.370 |
Why?
| Self-Injurious Behavior | 1 | 2012 | 114 | 0.370 |
Why?
| Cholinergic Antagonists | 1 | 2011 | 27 | 0.370 |
Why?
| Amitriptyline | 2 | 2001 | 21 | 0.370 |
Why?
| Blood Chemical Analysis | 3 | 2021 | 90 | 0.370 |
Why?
| Immunologic Factors | 2 | 2019 | 221 | 0.360 |
Why?
| Liver Failure | 1 | 2011 | 79 | 0.360 |
Why?
| Time Factors | 12 | 2020 | 6141 | 0.360 |
Why?
| Population Surveillance | 1 | 2013 | 392 | 0.360 |
Why?
| Tachycardia, Ventricular | 1 | 2012 | 153 | 0.360 |
Why?
| Cross-Sectional Studies | 9 | 2020 | 4411 | 0.360 |
Why?
| Anaphylaxis | 2 | 2012 | 148 | 0.360 |
Why?
| United States | 17 | 2023 | 12227 | 0.360 |
Why?
| Hydrofluoric Acid | 2 | 2016 | 8 | 0.350 |
Why?
| Pharmaceutical Vehicles | 1 | 2010 | 11 | 0.350 |
Why?
| Propylene Glycol | 1 | 2010 | 9 | 0.350 |
Why?
| Surveys and Questionnaires | 4 | 2018 | 4631 | 0.350 |
Why?
| Barium | 1 | 2009 | 25 | 0.350 |
Why?
| Risk Factors | 9 | 2017 | 8642 | 0.350 |
Why?
| Acidosis, Lactic | 1 | 2010 | 29 | 0.340 |
Why?
| Warfarin | 1 | 2010 | 135 | 0.340 |
Why?
| Explosive Agents | 1 | 2009 | 9 | 0.340 |
Why?
| Liver Diseases, Alcoholic | 2 | 2007 | 84 | 0.340 |
Why?
| Hypokalemia | 1 | 2009 | 25 | 0.340 |
Why?
| Length of Stay | 3 | 2020 | 951 | 0.340 |
Why?
| Imines | 2 | 2022 | 7 | 0.340 |
Why?
| Iatrogenic Disease | 1 | 2010 | 50 | 0.340 |
Why?
| Emetics | 2 | 2006 | 7 | 0.330 |
Why?
| Deception | 1 | 2009 | 16 | 0.330 |
Why?
| Risk Assessment | 8 | 2017 | 2976 | 0.330 |
Why?
| Random Allocation | 3 | 2007 | 336 | 0.330 |
Why?
| Benzoquinones | 2 | 2022 | 44 | 0.330 |
Why?
| Oximetry | 1 | 2009 | 81 | 0.320 |
Why?
| Odds Ratio | 7 | 2017 | 957 | 0.320 |
Why?
| Hypothermia, Induced | 1 | 2009 | 69 | 0.320 |
Why?
| Point-of-Care Systems | 1 | 2010 | 139 | 0.310 |
Why?
| Intellectual Disability | 1 | 2009 | 129 | 0.310 |
Why?
| Hypoglycemia | 2 | 2010 | 385 | 0.310 |
Why?
| Animals | 20 | 2019 | 31868 | 0.300 |
Why?
| Eyelashes | 1 | 2008 | 3 | 0.300 |
Why?
| Cyanoacrylates | 1 | 2008 | 4 | 0.300 |
Why?
| Reference Values | 4 | 2017 | 748 | 0.300 |
Why?
| Adhesives | 1 | 2008 | 11 | 0.300 |
Why?
| Detergents | 1 | 2008 | 41 | 0.300 |
Why?
| Polyethylene Glycols | 1 | 2012 | 561 | 0.300 |
Why?
| Cardiovascular System | 1 | 2009 | 126 | 0.300 |
Why?
| Publishing | 1 | 2009 | 125 | 0.290 |
Why?
| Brugada Syndrome | 1 | 2007 | 9 | 0.290 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 87 | 0.290 |
Why?
| Diazepam | 1 | 2007 | 26 | 0.290 |
Why?
| Niacin | 1 | 2007 | 18 | 0.290 |
Why?
| Pediatrics | 1 | 2015 | 981 | 0.280 |
Why?
| Mice, Inbred Strains | 4 | 2009 | 398 | 0.280 |
Why?
| Vitamin B Complex | 1 | 2007 | 37 | 0.280 |
Why?
| Specimen Handling | 1 | 2008 | 155 | 0.280 |
Why?
| Thromboembolism | 1 | 2007 | 93 | 0.280 |
Why?
| Analgesics | 4 | 2017 | 157 | 0.270 |
Why?
| Brain Infarction | 1 | 2006 | 22 | 0.270 |
Why?
| Anticoagulants | 1 | 2010 | 546 | 0.270 |
Why?
| Self Report | 4 | 2021 | 698 | 0.270 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2012 | 1215 | 0.270 |
Why?
| Hypoxia-Ischemia, Brain | 1 | 2006 | 26 | 0.270 |
Why?
| Acute Kidney Injury | 1 | 2012 | 638 | 0.260 |
Why?
| Age Factors | 7 | 2017 | 2894 | 0.260 |
Why?
| Nausea | 4 | 2014 | 102 | 0.260 |
Why?
| Intention | 1 | 2007 | 143 | 0.260 |
Why?
| Decontamination | 1 | 2006 | 23 | 0.260 |
Why?
| Databases, Factual | 1 | 2010 | 1132 | 0.260 |
Why?
| Epilepsy | 2 | 2020 | 278 | 0.260 |
Why?
| Venous Thrombosis | 1 | 2007 | 144 | 0.260 |
Why?
| Amiodarone | 1 | 2005 | 23 | 0.260 |
Why?
| Eating | 4 | 2017 | 347 | 0.260 |
Why?
| Biomarkers | 7 | 2021 | 3419 | 0.250 |
Why?
| Vasospasm, Intracranial | 1 | 2005 | 17 | 0.250 |
Why?
| Hypoglycemic Agents | 2 | 2010 | 1006 | 0.250 |
Why?
| Education, Medical | 2 | 2021 | 221 | 0.250 |
Why?
| Sodium Nitrite | 1 | 2005 | 37 | 0.250 |
Why?
| Diagnostic Imaging | 1 | 2007 | 290 | 0.240 |
Why?
| Drug Utilization | 5 | 2014 | 167 | 0.240 |
Why?
| Subarachnoid Hemorrhage | 1 | 2005 | 60 | 0.240 |
Why?
| Reproducibility of Results | 5 | 2011 | 2799 | 0.240 |
Why?
| Coma | 2 | 2006 | 30 | 0.240 |
Why?
| Insulin | 3 | 2019 | 2082 | 0.240 |
Why?
| Case-Control Studies | 4 | 2022 | 3015 | 0.230 |
Why?
| Hospitals, Urban | 5 | 2021 | 127 | 0.230 |
Why?
| Injections, Intraperitoneal | 4 | 2009 | 100 | 0.220 |
Why?
| Glasgow Coma Scale | 1 | 2004 | 144 | 0.220 |
Why?
| Anti-Anxiety Agents | 2 | 2020 | 43 | 0.220 |
Why?
| Animal Experimentation | 1 | 2003 | 6 | 0.220 |
Why?
| Fibrinolytic Agents | 2 | 2021 | 233 | 0.220 |
Why?
| Calcium Chloride | 1 | 2003 | 14 | 0.210 |
Why?
| Sensitivity and Specificity | 4 | 2010 | 1715 | 0.210 |
Why?
| Hospitals, Teaching | 3 | 2014 | 103 | 0.210 |
Why?
| Magnesium Sulfate | 1 | 2003 | 17 | 0.210 |
Why?
| Longevity | 3 | 2009 | 137 | 0.210 |
Why?
| Cardiopulmonary Resuscitation | 3 | 2018 | 220 | 0.210 |
Why?
| Umbilical Cord | 2 | 2021 | 80 | 0.200 |
Why?
| Logistic Models | 3 | 2017 | 1839 | 0.200 |
Why?
| Opiate Substitution Treatment | 2 | 2020 | 98 | 0.200 |
Why?
| Placebos | 2 | 2014 | 198 | 0.200 |
Why?
| Desipramine | 1 | 2001 | 9 | 0.200 |
Why?
| Phenylurea Compounds | 1 | 2022 | 82 | 0.200 |
Why?
| Severity of Illness Index | 1 | 2009 | 2551 | 0.200 |
Why?
| Research Design | 3 | 2006 | 930 | 0.200 |
Why?
| Hyperthermia, Induced | 1 | 2022 | 65 | 0.200 |
Why?
| Narcotic Antagonists | 2 | 2020 | 136 | 0.190 |
Why?
| Confidence Intervals | 4 | 2010 | 306 | 0.190 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2021 | 22 | 0.190 |
Why?
| Heart Atria | 1 | 2001 | 111 | 0.190 |
Why?
| Fractures, Bone | 2 | 2017 | 373 | 0.190 |
Why?
| Acute Disease | 2 | 2019 | 915 | 0.180 |
Why?
| Myocardial Contraction | 1 | 2001 | 313 | 0.180 |
Why?
| Mass Screening | 1 | 2007 | 1012 | 0.170 |
Why?
| Immunoglobulin Fragments | 1 | 1999 | 15 | 0.170 |
Why?
| Lysergic Acid Diethylamide | 1 | 1999 | 2 | 0.170 |
Why?
| Droperidol | 1 | 1999 | 4 | 0.170 |
Why?
| Wisconsin | 1 | 2020 | 91 | 0.170 |
Why?
| Lithium Carbonate | 1 | 1999 | 6 | 0.170 |
Why?
| Serotonin Syndrome | 1 | 1999 | 5 | 0.170 |
Why?
| Starch | 1 | 2019 | 20 | 0.170 |
Why?
| Serotonin Receptor Agonists | 1 | 1999 | 27 | 0.170 |
Why?
| Scorpion Stings | 1 | 1999 | 1 | 0.170 |
Why?
| Nutritive Value | 1 | 2019 | 30 | 0.170 |
Why?
| Geriatric Assessment | 2 | 2011 | 176 | 0.170 |
Why?
| Community Health Workers | 1 | 2020 | 45 | 0.170 |
Why?
| Ventricular Premature Complexes | 1 | 1999 | 26 | 0.170 |
Why?
| Administration, Oral | 4 | 2019 | 730 | 0.170 |
Why?
| Thrombocytopenia | 1 | 2021 | 178 | 0.170 |
Why?
| Healthy Volunteers | 2 | 2019 | 197 | 0.170 |
Why?
| Cannabidiol | 1 | 2020 | 60 | 0.170 |
Why?
| Metabolome | 1 | 2022 | 285 | 0.160 |
Why?
| Immune System | 1 | 2020 | 172 | 0.160 |
Why?
| Cohort Studies | 7 | 2023 | 4904 | 0.160 |
Why?
| Fallopian Tube Diseases | 1 | 1998 | 5 | 0.160 |
Why?
| Pregnancy, Tubal | 1 | 1998 | 5 | 0.160 |
Why?
| Alcoholism | 3 | 2011 | 716 | 0.160 |
Why?
| Sex Factors | 5 | 2022 | 1721 | 0.160 |
Why?
| Dietary Carbohydrates | 1 | 2019 | 136 | 0.160 |
Why?
| Abortifacient Agents, Nonsteroidal | 1 | 1998 | 19 | 0.160 |
Why?
| Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.160 |
Why?
| Plant Extracts | 1 | 2020 | 154 | 0.160 |
Why?
| Snake Bites | 1 | 1999 | 54 | 0.160 |
Why?
| Anticonvulsants | 1 | 2020 | 178 | 0.160 |
Why?
| Faculty, Medical | 1 | 2021 | 232 | 0.150 |
Why?
| Chi-Square Distribution | 2 | 2017 | 498 | 0.150 |
Why?
| Fellowships and Scholarships | 1 | 2021 | 227 | 0.150 |
Why?
| Sulfasalazine | 1 | 1998 | 21 | 0.150 |
Why?
| Genome-Wide Association Study | 2 | 2023 | 1203 | 0.150 |
Why?
| Drug Antagonism | 2 | 2009 | 8 | 0.150 |
Why?
| Dyspnea | 1 | 1999 | 218 | 0.150 |
Why?
| Drug Therapy, Combination | 3 | 2011 | 955 | 0.150 |
Why?
| Survival Rate | 3 | 2013 | 1646 | 0.150 |
Why?
| Incidence | 4 | 2013 | 2318 | 0.150 |
Why?
| Out-of-Hospital Cardiac Arrest | 1 | 2018 | 78 | 0.150 |
Why?
| Drug Interactions | 4 | 2014 | 347 | 0.150 |
Why?
| Dietary Fats | 1 | 2019 | 290 | 0.150 |
Why?
| Simulation Training | 1 | 2018 | 62 | 0.150 |
Why?
| Methotrexate | 1 | 1998 | 227 | 0.150 |
Why?
| Continuity of Patient Care | 1 | 2020 | 253 | 0.140 |
Why?
| Gastrointestinal Agents | 1 | 1998 | 60 | 0.140 |
Why?
| Hypnotics and Sedatives | 1 | 1998 | 134 | 0.140 |
Why?
| Peptide Fragments | 1 | 2021 | 668 | 0.140 |
Why?
| Energy Intake | 1 | 2019 | 421 | 0.140 |
Why?
| Pain Management | 2 | 2017 | 289 | 0.140 |
Why?
| Clinical Trials as Topic | 2 | 2012 | 937 | 0.140 |
Why?
| Mice | 7 | 2009 | 14928 | 0.140 |
Why?
| Ammonium Compounds | 1 | 2016 | 3 | 0.140 |
Why?
| Fluorides | 1 | 2016 | 43 | 0.140 |
Why?
| Prenatal Care | 1 | 2019 | 254 | 0.130 |
Why?
| Predictive Value of Tests | 3 | 2015 | 1812 | 0.130 |
Why?
| Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.130 |
Why?
| Survival Analysis | 3 | 2010 | 1211 | 0.130 |
Why?
| Metabolic Clearance Rate | 2 | 2019 | 106 | 0.130 |
Why?
| Ventricular Fibrillation | 1 | 2016 | 51 | 0.130 |
Why?
| Half-Life | 2 | 2019 | 143 | 0.130 |
Why?
| Pilot Projects | 1 | 2020 | 1375 | 0.130 |
Why?
| Pharmacovigilance | 1 | 2015 | 14 | 0.130 |
Why?
| Herniorrhaphy | 1 | 2016 | 49 | 0.130 |
Why?
| Calcium | 2 | 2016 | 1104 | 0.130 |
Why?
| Milk | 1 | 2016 | 124 | 0.130 |
Why?
| Genetic Variation | 1 | 2020 | 876 | 0.130 |
Why?
| Adverse Drug Reaction Reporting Systems | 1 | 2015 | 68 | 0.130 |
Why?
| Fatal Outcome | 2 | 2013 | 285 | 0.120 |
Why?
| Models, Biological | 2 | 2015 | 1636 | 0.120 |
Why?
| Child Behavior | 1 | 2017 | 219 | 0.120 |
Why?
| Internship and Residency | 2 | 2014 | 941 | 0.120 |
Why?
| Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.120 |
Why?
| Liver Failure, Acute | 1 | 2015 | 58 | 0.120 |
Why?
| Ondansetron | 1 | 2014 | 8 | 0.120 |
Why?
| Curriculum | 1 | 2021 | 843 | 0.120 |
Why?
| Patient Simulation | 1 | 2014 | 29 | 0.120 |
Why?
| Hydrocodone | 1 | 2014 | 15 | 0.120 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2014 | 24 | 0.120 |
Why?
| Personnel Staffing and Scheduling | 1 | 2015 | 79 | 0.120 |
Why?
| Prognosis | 3 | 2011 | 3335 | 0.120 |
Why?
| Total Quality Management | 1 | 1994 | 62 | 0.120 |
Why?
| Physicians | 2 | 2020 | 772 | 0.120 |
Why?
| Pregnancy Complications | 1 | 2019 | 430 | 0.120 |
Why?
| Transaminases | 1 | 2014 | 25 | 0.120 |
Why?
| Oxycodone | 1 | 2014 | 44 | 0.110 |
Why?
| Acute Pain | 1 | 2014 | 34 | 0.110 |
Why?
| Guanfacine | 1 | 2013 | 2 | 0.110 |
Why?
| Remote Consultation | 1 | 2014 | 42 | 0.110 |
Why?
| Vitamins | 1 | 2015 | 151 | 0.110 |
Why?
| Walking | 1 | 2017 | 424 | 0.110 |
Why?
| Clonidine | 1 | 2013 | 26 | 0.110 |
Why?
| International Normalized Ratio | 2 | 2011 | 45 | 0.110 |
Why?
| Indazoles | 1 | 2014 | 58 | 0.110 |
Why?
| Cesium | 1 | 2013 | 16 | 0.110 |
Why?
| Attitude of Health Personnel | 1 | 2020 | 976 | 0.110 |
Why?
| Food | 1 | 2015 | 160 | 0.110 |
Why?
| Pain Measurement | 4 | 2019 | 448 | 0.110 |
Why?
| Deoxycholic Acid | 1 | 2013 | 15 | 0.110 |
Why?
| Lethargy | 1 | 2012 | 4 | 0.110 |
Why?
| Duloxetine Hydrochloride | 1 | 2012 | 8 | 0.110 |
Why?
| Dabigatran | 1 | 2012 | 22 | 0.110 |
Why?
| Pyrazoles | 1 | 2016 | 362 | 0.110 |
Why?
| Chlorides | 1 | 2013 | 127 | 0.100 |
Why?
| Athletic Performance | 1 | 2013 | 44 | 0.100 |
Why?
| Tachycardia | 1 | 2012 | 50 | 0.100 |
Why?
| Marijuana Abuse | 1 | 2015 | 212 | 0.100 |
Why?
| Sleep Stages | 1 | 2012 | 61 | 0.100 |
Why?
| Mycoses | 1 | 2013 | 66 | 0.100 |
Why?
| Patient Discharge | 2 | 2016 | 767 | 0.100 |
Why?
| Sulfhydryl Reagents | 1 | 2012 | 11 | 0.100 |
Why?
| Data Collection | 2 | 2013 | 623 | 0.100 |
Why?
| Dizziness | 1 | 2012 | 70 | 0.100 |
Why?
| Accidental Falls | 2 | 2011 | 150 | 0.100 |
Why?
| Follow-Up Studies | 3 | 2010 | 4420 | 0.100 |
Why?
| Arsenicals | 1 | 2012 | 24 | 0.100 |
Why?
| Sampling Studies | 1 | 2012 | 94 | 0.100 |
Why?
| Drug Combinations | 1 | 2013 | 287 | 0.100 |
Why?
| Laparoscopy | 1 | 2016 | 387 | 0.100 |
Why?
| Information Systems | 1 | 2011 | 61 | 0.100 |
Why?
| Sulfides | 1 | 2012 | 94 | 0.100 |
Why?
| Marijuana Smoking | 1 | 2015 | 224 | 0.100 |
Why?
| Dietary Supplements | 1 | 2015 | 458 | 0.090 |
Why?
| Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| Structure-Activity Relationship | 1 | 2012 | 503 | 0.090 |
Why?
| Hepatic Encephalopathy | 1 | 2011 | 19 | 0.090 |
Why?
| Levamisole | 1 | 2011 | 20 | 0.090 |
Why?
| Immunocompromised Host | 1 | 2013 | 196 | 0.090 |
Why?
| Molecular Structure | 1 | 2012 | 438 | 0.090 |
Why?
| Drug Contamination | 1 | 2011 | 53 | 0.090 |
Why?
| Sports | 1 | 2013 | 178 | 0.090 |
Why?
| Universities | 1 | 2013 | 339 | 0.090 |
Why?
| Pharmacogenetics | 1 | 2012 | 149 | 0.090 |
Why?
| Glipizide | 1 | 2010 | 6 | 0.090 |
Why?
| Laboratories, Hospital | 1 | 2010 | 13 | 0.090 |
Why?
| Hepatitis, Alcoholic | 1 | 2010 | 13 | 0.090 |
Why?
| Troponin | 1 | 2010 | 44 | 0.090 |
Why?
| Glyburide | 1 | 2010 | 35 | 0.090 |
Why?
| Drug Prescriptions | 2 | 2016 | 239 | 0.090 |
Why?
| Crowding | 1 | 2010 | 37 | 0.090 |
Why?
| Watchful Waiting | 1 | 2010 | 56 | 0.090 |
Why?
| Body Weight | 1 | 2014 | 873 | 0.090 |
Why?
| Adjuvants, Immunologic | 1 | 2011 | 206 | 0.090 |
Why?
| Intensive Care Units, Pediatric | 1 | 2011 | 147 | 0.080 |
Why?
| Health Services Accessibility | 1 | 2015 | 765 | 0.080 |
Why?
| Quetiapine Fumarate | 1 | 2009 | 22 | 0.080 |
Why?
| Dibenzothiazepines | 1 | 2009 | 17 | 0.080 |
Why?
| Aripiprazole | 1 | 2009 | 17 | 0.080 |
Why?
| Risperidone | 1 | 2009 | 26 | 0.080 |
Why?
| Dogs | 1 | 2010 | 340 | 0.080 |
Why?
| Renal Dialysis | 1 | 2013 | 369 | 0.080 |
Why?
| Potassium | 1 | 2009 | 128 | 0.080 |
Why?
| Efficiency, Organizational | 1 | 2010 | 124 | 0.080 |
Why?
| Head Protective Devices | 1 | 2009 | 14 | 0.080 |
Why?
| Glutathione | 3 | 2022 | 302 | 0.080 |
Why?
| Role | 1 | 2009 | 32 | 0.080 |
Why?
| Quality Control | 1 | 2009 | 144 | 0.080 |
Why?
| Workload | 1 | 2010 | 132 | 0.080 |
Why?
| Bibliometrics | 1 | 2009 | 44 | 0.080 |
Why?
| Body Temperature | 1 | 2009 | 210 | 0.080 |
Why?
| Acidosis | 2 | 2006 | 87 | 0.080 |
Why?
| Diarrhea | 1 | 2009 | 171 | 0.080 |
Why?
| Quality Indicators, Health Care | 1 | 2011 | 287 | 0.080 |
Why?
| Skiing | 1 | 2009 | 41 | 0.080 |
Why?
| Students | 1 | 2013 | 499 | 0.080 |
Why?
| Informed Consent | 2 | 2006 | 161 | 0.080 |
Why?
| Pharmacy Service, Hospital | 1 | 2009 | 84 | 0.080 |
Why?
| Acetone | 1 | 2008 | 10 | 0.080 |
Why?
| Hair Preparations | 1 | 2008 | 2 | 0.080 |
Why?
| Bacitracin | 1 | 2008 | 6 | 0.080 |
Why?
| Adhesiveness | 1 | 2008 | 19 | 0.080 |
Why?
| Cause of Death | 1 | 2010 | 364 | 0.080 |
Why?
| Nylons | 1 | 2008 | 18 | 0.080 |
Why?
| Propylene Glycols | 1 | 2008 | 25 | 0.070 |
Why?
| Quinolones | 1 | 2009 | 97 | 0.070 |
Why?
| Withholding Treatment | 1 | 2008 | 69 | 0.070 |
Why?
| Substance Abuse Detection | 2 | 2021 | 62 | 0.070 |
Why?
| Equipment Design | 1 | 2009 | 513 | 0.070 |
Why?
| Drug Synergism | 1 | 2008 | 317 | 0.070 |
Why?
| Glycerol | 1 | 2008 | 84 | 0.070 |
Why?
| Cellulose | 1 | 2008 | 57 | 0.070 |
Why?
| Nephelometry and Turbidimetry | 1 | 2007 | 16 | 0.070 |
Why?
| Hospitalization | 2 | 2011 | 1755 | 0.070 |
Why?
| Laboratories | 1 | 2008 | 95 | 0.070 |
Why?
| Military Personnel | 1 | 2014 | 523 | 0.070 |
Why?
| Polypharmacy | 1 | 2008 | 74 | 0.070 |
Why?
| Tissue Distribution | 2 | 2019 | 286 | 0.070 |
Why?
| Phosphates | 1 | 2008 | 159 | 0.070 |
Why?
| Research | 2 | 2011 | 395 | 0.070 |
Why?
| Kidney Transplantation | 1 | 2013 | 549 | 0.070 |
Why?
| Periodicals as Topic | 1 | 2009 | 181 | 0.070 |
Why?
| Formates | 1 | 2006 | 12 | 0.070 |
Why?
| Combined Modality Therapy | 1 | 2009 | 1127 | 0.070 |
Why?
| Methanol | 1 | 2006 | 29 | 0.070 |
Why?
| Defibrillators | 1 | 2006 | 16 | 0.070 |
Why?
| Aging | 2 | 2014 | 1624 | 0.070 |
Why?
| Blindness | 1 | 2006 | 37 | 0.070 |
Why?
| Vasopressins | 1 | 2006 | 56 | 0.070 |
Why?
| Statistics, Nonparametric | 1 | 2007 | 387 | 0.070 |
Why?
| Telemedicine | 1 | 2014 | 665 | 0.070 |
Why?
| Naproxen | 1 | 2006 | 11 | 0.070 |
Why?
| Probability | 2 | 2010 | 289 | 0.070 |
Why?
| Respiratory Insufficiency | 1 | 2009 | 290 | 0.070 |
Why?
| Health Services for the Aged | 1 | 2006 | 70 | 0.070 |
Why?
| Ipecac | 1 | 2005 | 8 | 0.070 |
Why?
| Spinal Diseases | 1 | 2006 | 44 | 0.070 |
Why?
| Population Dynamics | 1 | 2006 | 128 | 0.070 |
Why?
| Respiration, Artificial | 1 | 2009 | 526 | 0.070 |
Why?
| Geriatrics | 1 | 2006 | 69 | 0.060 |
Why?
| Epinephrine | 1 | 2006 | 167 | 0.060 |
Why?
| Practice Guidelines as Topic | 2 | 2014 | 1398 | 0.060 |
Why?
| Ibuprofen | 1 | 2006 | 73 | 0.060 |
Why?
| Hospitals, University | 1 | 2006 | 170 | 0.060 |
Why?
| Haplorhini | 1 | 2005 | 57 | 0.060 |
Why?
| Premedication | 1 | 2005 | 36 | 0.060 |
Why?
| Blood Glucose | 2 | 2019 | 1821 | 0.060 |
Why?
| Spine | 1 | 2006 | 139 | 0.060 |
Why?
| Risk | 1 | 2007 | 815 | 0.060 |
Why?
| Motivation | 1 | 2009 | 498 | 0.060 |
Why?
| Water | 1 | 2008 | 409 | 0.060 |
Why?
| Single-Blind Method | 1 | 2005 | 258 | 0.060 |
Why?
| Fluoride Poisoning | 1 | 2004 | 4 | 0.060 |
Why?
| Resuscitation | 1 | 2006 | 248 | 0.060 |
Why?
| Pregnancy | 3 | 2021 | 5520 | 0.060 |
Why?
| Guidelines as Topic | 1 | 2005 | 245 | 0.060 |
Why?
| Maltose | 1 | 2023 | 5 | 0.060 |
Why?
| Hydroxyzine | 1 | 2023 | 6 | 0.060 |
Why?
| Health Policy | 1 | 2006 | 334 | 0.060 |
Why?
| Mycophenolic Acid | 1 | 2004 | 78 | 0.050 |
Why?
| Magnesium | 1 | 2004 | 145 | 0.050 |
Why?
| Sheep | 1 | 2006 | 764 | 0.050 |
Why?
| Aspirin | 1 | 2006 | 324 | 0.050 |
Why?
| Urea | 1 | 2023 | 68 | 0.050 |
Why?
| Survival | 1 | 2003 | 37 | 0.050 |
Why?
| Patient Participation | 1 | 2006 | 360 | 0.050 |
Why?
| Prevalence | 3 | 2015 | 2255 | 0.050 |
Why?
| Internet | 1 | 2007 | 600 | 0.050 |
Why?
| Urban Population | 2 | 2019 | 401 | 0.050 |
Why?
| Canada | 1 | 2023 | 322 | 0.050 |
Why?
| Lactates | 1 | 2022 | 84 | 0.050 |
Why?
| Sex Distribution | 2 | 2015 | 335 | 0.050 |
Why?
| Culture Techniques | 1 | 2001 | 80 | 0.050 |
Why?
| Breast Neoplasms | 1 | 2013 | 1865 | 0.050 |
Why?
| Blood Physiological Phenomena | 1 | 2021 | 14 | 0.050 |
Why?
| Academic Medical Centers | 2 | 2016 | 412 | 0.050 |
Why?
| Neural Conduction | 1 | 2001 | 79 | 0.050 |
Why?
| Hirudins | 1 | 2021 | 46 | 0.050 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2020 | 27 | 0.040 |
Why?
| Infusions, Parenteral | 1 | 2020 | 37 | 0.040 |
Why?
| Certification | 1 | 2020 | 89 | 0.040 |
Why?
| Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| Ambulatory Care | 1 | 2023 | 478 | 0.040 |
Why?
| Scorpions | 1 | 1999 | 2 | 0.040 |
Why?
| Immunosuppressive Agents | 1 | 2004 | 651 | 0.040 |
Why?
| Temperature | 1 | 2022 | 578 | 0.040 |
Why?
| South America | 1 | 1999 | 51 | 0.040 |
Why?
| Blood Cell Count | 2 | 2013 | 51 | 0.040 |
Why?
| Narcotics | 1 | 1999 | 44 | 0.040 |
Why?
| Postprandial Period | 1 | 2019 | 88 | 0.040 |
Why?
| Biological Availability | 1 | 2019 | 119 | 0.040 |
Why?
| Rupture, Spontaneous | 1 | 1998 | 16 | 0.040 |
Why?
| Manikins | 1 | 2018 | 24 | 0.040 |
Why?
| Videotape Recording | 1 | 2018 | 30 | 0.040 |
Why?
| Central Nervous System Depressants | 1 | 1999 | 82 | 0.040 |
Why?
| Sorption Detoxification | 1 | 1998 | 3 | 0.040 |
Why?
| Analysis of Variance | 1 | 2001 | 1229 | 0.040 |
Why?
| Lipids | 1 | 2022 | 586 | 0.040 |
Why?
| Dietary Proteins | 1 | 2019 | 123 | 0.040 |
Why?
| North America | 1 | 1999 | 259 | 0.040 |
Why?
| Cholinesterase Inhibitors | 1 | 1998 | 23 | 0.040 |
Why?
| Laparotomy | 1 | 1998 | 97 | 0.040 |
Why?
| Feedback | 1 | 2018 | 146 | 0.040 |
Why?
| Recombinant Proteins | 1 | 2021 | 1237 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2019 | 441 | 0.040 |
Why?
| Maternal Health Services | 1 | 2019 | 78 | 0.040 |
Why?
| Central Nervous System | 1 | 1999 | 238 | 0.040 |
Why?
| Triglycerides | 1 | 2019 | 471 | 0.040 |
Why?
| Socioeconomic Factors | 2 | 2015 | 1081 | 0.040 |
Why?
| Registries | 2 | 2010 | 1763 | 0.040 |
Why?
| Bipolar Disorder | 1 | 1999 | 208 | 0.040 |
Why?
| Oxidation-Reduction | 1 | 2019 | 926 | 0.030 |
Why?
| Hallucinogens | 1 | 2017 | 73 | 0.030 |
Why?
| Dialysis | 1 | 2015 | 17 | 0.030 |
Why?
| Centrifugation | 1 | 2015 | 31 | 0.030 |
Why?
| Verapamil | 1 | 2014 | 32 | 0.030 |
Why?
| Tennessee | 1 | 1994 | 38 | 0.030 |
Why?
| Observation | 1 | 2014 | 49 | 0.030 |
Why?
| Hematocrit | 1 | 1994 | 85 | 0.030 |
Why?
| Protein Binding | 1 | 2020 | 1898 | 0.030 |
Why?
| International Classification of Diseases | 1 | 2015 | 116 | 0.030 |
Why?
| Program Evaluation | 1 | 2018 | 825 | 0.030 |
Why?
| Syndrome | 1 | 2015 | 337 | 0.030 |
Why?
| Anesthetics, Local | 1 | 2014 | 84 | 0.030 |
Why?
| Erythropoietin | 1 | 1994 | 72 | 0.030 |
Why?
| Warfare | 1 | 2014 | 75 | 0.030 |
Why?
| Injections, Intralesional | 1 | 2013 | 32 | 0.030 |
Why?
| Hospitals, Veterans | 1 | 1994 | 244 | 0.030 |
Why?
| Salicylates | 1 | 2013 | 30 | 0.030 |
Why?
| Iron | 1 | 1994 | 234 | 0.030 |
Why?
| Urinalysis | 1 | 2013 | 63 | 0.030 |
Why?
| Nursing Staff, Hospital | 1 | 1994 | 122 | 0.030 |
Why?
| Long QT Syndrome | 1 | 2013 | 59 | 0.030 |
Why?
| Hemoglobins | 1 | 1994 | 315 | 0.030 |
Why?
| Therapeutic Irrigation | 1 | 2012 | 67 | 0.020 |
Why?
| Receptors, Opioid, mu | 1 | 2012 | 52 | 0.020 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2012 | 108 | 0.020 |
Why?
| Computer Simulation | 1 | 2015 | 881 | 0.020 |
Why?
| Insulin Resistance | 1 | 2019 | 1077 | 0.020 |
Why?
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 7 | 0.020 |
Why?
| False Negative Reactions | 1 | 2011 | 50 | 0.020 |
Why?
| Agranulocytosis | 1 | 2011 | 31 | 0.020 |
Why?
| Fluid Therapy | 1 | 2012 | 122 | 0.020 |
Why?
| Disease Outbreaks | 1 | 2014 | 309 | 0.020 |
Why?
| Leukoencephalopathies | 1 | 2011 | 21 | 0.020 |
Why?
| Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| Quality of Health Care | 1 | 2015 | 573 | 0.020 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2011 | 125 | 0.020 |
Why?
| Immunoassay | 1 | 2011 | 95 | 0.020 |
Why?
| Models, Theoretical | 1 | 1994 | 517 | 0.020 |
Why?
| Drug Administration Routes | 1 | 2010 | 40 | 0.020 |
Why?
| Insurance Coverage | 1 | 2012 | 201 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2010 | 202 | 0.020 |
Why?
| Patient Education as Topic | 1 | 1994 | 682 | 0.020 |
Why?
| Neurologic Examination | 1 | 2010 | 115 | 0.020 |
Why?
| Kidney Failure, Chronic | 1 | 1994 | 489 | 0.020 |
Why?
| Age Distribution | 1 | 2010 | 340 | 0.020 |
Why?
| Intestines | 1 | 2012 | 322 | 0.020 |
Why?
| Polymorphism, Genetic | 1 | 2012 | 617 | 0.020 |
Why?
| Precision Medicine | 1 | 2012 | 340 | 0.020 |
Why?
| Safety | 1 | 2010 | 297 | 0.020 |
Why?
| Ethanol | 1 | 2012 | 548 | 0.020 |
Why?
| Clinical Competence | 1 | 2014 | 899 | 0.020 |
Why?
| Triage | 1 | 2010 | 192 | 0.020 |
Why?
| Seasons | 1 | 2010 | 448 | 0.020 |
Why?
| Regression Analysis | 1 | 2010 | 948 | 0.020 |
Why?
| Disease Management | 1 | 2011 | 563 | 0.020 |
Why?
| Metabolomics | 1 | 2012 | 527 | 0.020 |
Why?
| Bilirubin | 1 | 2007 | 88 | 0.020 |
Why?
| Pulse | 1 | 2006 | 27 | 0.020 |
Why?
| Genotype | 1 | 2012 | 1780 | 0.020 |
Why?
| Blastomycosis | 1 | 2006 | 8 | 0.020 |
Why?
| Contraindications | 1 | 2006 | 86 | 0.020 |
Why?
| Infant, Newborn | 2 | 2007 | 5040 | 0.020 |
Why?
| Amyloidosis | 1 | 2006 | 36 | 0.020 |
Why?
| Coronary Circulation | 1 | 2006 | 135 | 0.020 |
Why?
| Biopsy, Fine-Needle | 1 | 2006 | 64 | 0.020 |
Why?
| Electric Countershock | 1 | 2006 | 104 | 0.020 |
Why?
| European Union | 1 | 2005 | 8 | 0.020 |
Why?
| Fever | 1 | 2007 | 280 | 0.020 |
Why?
| Disaster Planning | 1 | 2006 | 74 | 0.020 |
Why?
| Emergencies | 1 | 2006 | 147 | 0.020 |
Why?
| United States Food and Drug Administration | 1 | 2005 | 172 | 0.020 |
Why?
| Administration, Inhalation | 1 | 2006 | 641 | 0.020 |
Why?
| Renal Insufficiency | 1 | 2006 | 136 | 0.010 |
Why?
| Up-Regulation | 1 | 2007 | 812 | 0.010 |
Why?
| Swine | 1 | 2006 | 704 | 0.010 |
Why?
| Phenotype | 1 | 2012 | 2815 | 0.010 |
Why?
| Pharmaceutical Preparations | 1 | 2006 | 169 | 0.010 |
Why?
| Brain Injuries | 1 | 2009 | 452 | 0.010 |
Why?
| Mice, Inbred ICR | 1 | 2004 | 109 | 0.010 |
Why?
| Lupus Nephritis | 1 | 2004 | 52 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2004 | 1036 | 0.010 |
Why?
| Blood Pressure | 1 | 2006 | 1539 | 0.010 |
Why?
| Miosis | 1 | 1999 | 3 | 0.010 |
Why?
| Pupil | 1 | 1999 | 13 | 0.010 |
Why?
| Hemodynamics | 1 | 2004 | 1017 | 0.010 |
Why?
| Chronic Disease | 1 | 2004 | 1591 | 0.010 |
Why?
| Algorithms | 1 | 2004 | 1489 | 0.010 |
Why?
| Neoplasms | 1 | 2006 | 2106 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) Derived automatically from this person's publications. _
Co-Authors ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People in Profiles who have published with this person. _
Similar People ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People whose addresses are nearby this person. _
|